Patents by Inventor Dror Harats

Dror Harats has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210069330
    Abstract: Disclosed herein are methods and compositions for radiosensitizing tumor in subjects receiving radiation therapy by administering a gene therapy construct that results in expression of a secretory radiosensitizing agent in tumor endothelium.
    Type: Application
    Filed: August 27, 2020
    Publication date: March 11, 2021
    Inventors: Richard N. KOLESNICK, Branka STANCEVIC, Michel SADELAIN, Zvi FUKS, Nira VARDA-BLOOM, Dror HARATS
  • Publication number: 20180015183
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: July 6, 2017
    Publication date: January 18, 2018
    Applicants: MEMORIAL SLOANE-KETTERING CANCER CENTER, Vascular Biogenics Ltd.
    Inventors: Richard N. KOLESNICK, Branka STANCEVIC, Michel SADELAIN, Zvi FUKS, Nira VARDA-BLOOM, Dror HARATS
  • Publication number: 20180015184
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 18, 2018
    Inventors: Richard N. Kolesnick, Branka Stancevic, Michel Sadelain, Zvi Fuks, Nira Varda-Bloom, Dror Harats
  • Publication number: 20170007718
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: September 4, 2015
    Publication date: January 12, 2017
    Inventors: Richard N. Kolesnick, Branka Stancevic, Michel Sadelain, Zvi Fuks, Nira Varda-Bloom, Dror Harats
  • Publication number: 20160279202
    Abstract: The invention provides IL-1 inhibitors, methods and uses thereof for retaining ovarian follicle reserve in a mammalian subject, treating infertility and improving responsiveness and sensitivity to COH. The invention further provides methods for improving oocyte quality and/or survival, specifically for IVF, and kits for combining COH treatment with the sensitizing IL-inhibitors of the invention.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 29, 2016
    Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND S ERVICES LTD.
    Inventors: Yehuda KAMARI, Ruth SHALGI, Shiri URI, Dror HARATS, Aviv SHAISH
  • Patent number: 9180152
    Abstract: The invention is a method for treating psoriasis in a subject suffering from psoriasis. The method includes orally administering to the subject a pharmaceutically-effective amount of crude Dunaliella powder.
    Type: Grant
    Filed: December 5, 2010
    Date of Patent: November 10, 2015
    Assignees: NIKKEN SOHONSHA CORPORATION, TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Aviv Shaish, Dror Harats, Shoshana Greenberger
  • Patent number: 8961993
    Abstract: Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crude Dunaliella powder is also provided.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: February 24, 2015
    Assignees: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure and Services Ltd.
    Inventors: Michael Belkin, Aviv Shaish, Dror Harats, Ygal Rotenstreich
  • Patent number: 8916378
    Abstract: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: December 23, 2014
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart
  • Patent number: 8859745
    Abstract: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: October 14, 2014
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Eyal Breitbart, Nira Bloom
  • Patent number: 8859747
    Abstract: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 14, 2014
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Eyal Breitbart, Nira Bloom
  • Patent number: 8846401
    Abstract: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: September 30, 2014
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Eyal Breitbart, Nira Bloom
  • Patent number: 8835398
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 16, 2014
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Publication number: 20140155467
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: October 21, 2013
    Publication date: June 5, 2014
    Applicant: VASCULAR BIOGENICS LTD.
    Inventors: Dror HARATS, Shoshana GREENBERGER, Eyal BREITBART, Livnat BANGIO, Michael PELED
  • Publication number: 20140023702
    Abstract: Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crude Dunaliella powder is also provided.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 23, 2014
    Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., NIKKEN SOHONSHA CORPORATION
    Inventors: Michael BELKIN, Aviv SHAISH, Dror HARATS, Ygal ROTENSTREICH
  • Publication number: 20130296404
    Abstract: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.
    Type: Application
    Filed: March 13, 2013
    Publication date: November 7, 2013
    Inventors: Dror HARATS, Eyal Breitbart, Nira Bloom
  • Patent number: 8563534
    Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: October 22, 2013
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
  • Patent number: 8529907
    Abstract: Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crude Dunaliella powder is also provided.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 10, 2013
    Assignees: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure and Services Ltd.
    Inventors: Michael Belkin, Aviv Shaish, Dror Harats, Ygal Rotenstreich
  • Patent number: 8501715
    Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: August 6, 2013
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Jacob George, Gideon Halperin, Itzhak Mendel, Niva Yacov, Eti Kovalevski-Ishai
  • Patent number: 8415318
    Abstract: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: April 9, 2013
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart
  • Publication number: 20130011367
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: July 13, 2012
    Publication date: January 10, 2013
    Applicant: Vascular Biogenics, Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled